Literature DB >> 12003715

Inflammatory Bowel Disease: Future Therapies.

Sander J.H. Van Deventer1.   

Abstract

Current medical therapies for people with inflammatory bowel disease are not satisfactory, and it is unlikely that improvement of traditional drugs will have a major clinical impact. The immunopathogensis of Crohn's disease and ulcerative colitis are rapidly being deciphered, which is providing oppurtunities for radically innovative therapeutic approaches.

Entities:  

Year:  2002        PMID： 12003715     DOI： 10.1007/s11938-002-0042-x

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN： 1092-8472


  49 in total

1.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease.

Authors:  M Chehade; K Benkov
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-02       Impact factor: 2.839

Review 2.  Non-Th2 regulatory T-cell control of Th1 autoimmunity.

Authors:  J F Bach
Journal:  Scand J Immunol       Date:  2001 Jul-Aug       Impact factor: 3.487

3.  A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood.

Authors:  S Yamagiwa; J D Gray; S Hashimoto; D A Horwitz
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

Review 4.  The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease.

Authors:  R P MacDermott; I R Sanderson; H C Reinecker
Journal:  Inflamm Bowel Dis       Date:  1998-02       Impact factor: 5.325

5.  Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region.

Authors:  A Poltorak; I Smirnova; X He; M Y Liu; C Van Huffel; O McNally; D Birdwell; E Alejos; M Silva; X Du; P Thompson; E K Chan; J Ledesma; B Roe; S Clifton; S N Vogel; B Beutler
Journal:  Blood Cells Mol Dis       Date:  1998-09       Impact factor: 3.039

6.  Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.

Authors:  W F Ng; P J Duggan; F Ponchel; G Matarese; G Lombardi; A D Edwards; J D Isaacs; R I Lechler
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

7.  Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis.

Authors:  M Boirivant; M Marini; G Di Felice; A M Pronio; C Montesani; R Tersigni; W Strober
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

8.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

9.  Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease.

Authors:  P Gibson; O Rosella
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

10.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.

Authors:  H Groux; M Bigler; J E de Vries; M G Roncarolo
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307
View more
  1 in total

1.  Cholinergic Anti-Inflammatory Pathway Does Not Contribute to Prevention of Ulcerative Colitis by Novel Indoline Carbamates.

Authors:  Helena Shifrin; Odelia Mouhadeb; Nathan Gluck; Chen Varol; Marta Weinstock
Journal:  J Neuroimmune Pharmacol       Date:  2017-03-07       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.